Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812927 | 0.84 | CYP19A1 (0.37) | ESR1ALDH1A1RAB9AMAPTMAPK1 | |
| SCHEMBL12960161 | 0.81 | PARP1 (0.40) | ALDH1A1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL12678013 | 0.81 | PARP1 (0.40) | ALDH1A1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL12960192 | 0.80 | CYP19A1 (0.40) | ALDH1A1RAB9ANPSR1L3MBTL1CYP19A1 | |
| SCHEMBL13056369 | 0.80 | HPGD (0.39) | ESR1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL11947263 | 0.80 | MAOB (0.54) | PTGS2ALDH1A1RAB9AMAPTLMNA | |
| SCHEMBL31236807 | 0.76 | CYP17A1 (0.38) | MAPTMAPK1LMNACYP19A1SMN1; SMN2 | |
| SCHEMBL813089 | 0.74 | SMN1; SMN2 (0.37) | ALDH1A1RAB9AMAPTMAPK1LMNA | |
| SCHEMBL13171739 | 0.73 | ALDH1A1 (0.32) | ALDH1A1MAPTLMNAXBP1NPSR1 | |
| SCHEMBL12103739 | 0.73 | CES2 (0.43) | ALDH1A1RAB9AMAPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005277-A1 | Protein Kinase Inhibitors and Uses Thereof | BEIGENE, LTD. (KY) | 2015-01-01 | — | — | US | disclosed |
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7179836-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005277-A1 | Protein Kinase Inhibitors and Uses Thereof | BTK, ABL1, PRKACA | ESR1 3880/4885PTGS2 2224/4885ALDH1A1 4202/4885 |
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | INCENP, CYBA, ADCY5 | ESR1 815/4885PTGS2 890/4885ALDH1A1 371/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | ESR1 1783/4885PTGS2 205/4885ALDH1A1 1144/4885 |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | INCENP, CYBA, PAICS | ESR1 908/4885PTGS2 891/4885ALDH1A1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.